Key Points
- Director Mark Saad sold 37,577 shares on Dec. 31 at an average price of $165.18 for a total of $6,206,968.86, reducing his position by 78.98% and leaving him with 10,002 shares (~$1.65M).
- In the most recent quarter Axsome reported EPS of -$0.94, missing the consensus by $0.12 while posting revenue of $170.99M (up 63.2% year-over-year), and remains unprofitable with a negative net margin and return on equity.
- Wall Street sentiment is generally positive—the stock has a consensus rating of "Moderate Buy" with an average target of $183.94—while institutional investors own roughly 81.5% of the shares and the company has a market cap near $9.0B.
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) Director Mark Saad sold 37,577 shares of the company's stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $165.18, for a total value of $6,206,968.86. Following the completion of the sale, the director owned 10,002 shares in the company, valued at $1,652,130.36. The trade was a 78.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Axsome Therapeutics Stock Down 2.2%
Shares of NASDAQ:AXSM opened at $178.69 on Friday. The stock has a fifty day simple moving average of $147.29 and a two-hundred day simple moving average of $125.45. The stock has a market capitalization of $9.01 billion, a price-to-earnings ratio of -38.26, a PEG ratio of 16.17 and a beta of 0.48. Axsome Therapeutics, Inc. has a 12-month low of $79.19 and a 12-month high of $184.40. The company has a current ratio of 1.57, a quick ratio of 1.50 and a debt-to-equity ratio of 1.66.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.12). The company had revenue of $170.99 million for the quarter, compared to the consensus estimate of $162.96 million. Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. The business's revenue was up 63.2% compared to the same quarter last year. On average, research analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on AXSM shares. Mizuho set a $217.00 target price on shares of Axsome Therapeutics in a research note on Wednesday. Wells Fargo & Company decreased their price objective on shares of Axsome Therapeutics from $163.00 to $157.00 and set an "overweight" rating for the company in a report on Tuesday, November 4th. HC Wainwright increased their target price on Axsome Therapeutics from $180.00 to $185.00 and gave the company a "buy" rating in a research note on Tuesday, November 4th. Oppenheimer reissued an "outperform" rating and issued a $220.00 target price on shares of Axsome Therapeutics in a report on Wednesday. Finally, Cowen restated a "buy" rating on shares of Axsome Therapeutics in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $183.94.
View Our Latest Analysis on Axsome Therapeutics
Institutional Investors Weigh In On Axsome Therapeutics
A number of hedge funds have recently added to or reduced their stakes in AXSM. Swiss National Bank raised its stake in Axsome Therapeutics by 6.9% during the 2nd quarter. Swiss National Bank now owns 65,200 shares of the company's stock worth $6,806,000 after acquiring an additional 4,200 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Axsome Therapeutics by 55.4% in the second quarter. Bank of New York Mellon Corp now owns 203,632 shares of the company's stock worth $21,257,000 after purchasing an additional 72,609 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in shares of Axsome Therapeutics by 62.9% in the third quarter. Assenagon Asset Management S.A. now owns 294,771 shares of the company's stock worth $35,800,000 after purchasing an additional 113,811 shares in the last quarter. Los Angeles Capital Management LLC raised its position in shares of Axsome Therapeutics by 154.5% during the 2nd quarter. Los Angeles Capital Management LLC now owns 4,424 shares of the company's stock valued at $462,000 after purchasing an additional 2,686 shares during the period. Finally, KLP Kapitalforvaltning AS lifted its stake in shares of Axsome Therapeutics by 36.6% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 11,200 shares of the company's stock valued at $1,169,000 after buying an additional 3,000 shares in the last quarter. 81.49% of the stock is currently owned by hedge funds and other institutional investors.
Axsome Therapeutics Company Profile
(
Get Free Report)
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.
Axsome's pipeline includes several late-stage and approved product candidates.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
